A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #204

Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry.

Kwok WH, Ho EN, Lau MY, et al. Analytical and bioanalytical chemistry. 2013.

Editor's note

A doping-control analytical study in horses, not a clinical or efficacy trial. Researchers developed a cost-saving extraction and mass-spectrometry method to detect seven bioactive peptides — including ipamorelin, hexarelin, GHRP-6, CJC-1295, and the acetylated LKKTETQ fragment that is TB-500's active ingredient — in horse plasma, avoiding expensive antibody-based purification. The one in-vivo element of note: two thoroughbred geldings received 10 mg subcutaneous TB-500, and the method detected the parent fragment and a metabolite in their plasma. That is a detectability demonstration in horses, not a study of what TB-500 does. For readers, this bears on surveillance and forensic capability, not human clinical benefit or safety. It is a useful reminder that TB-500 and these GH-secretagogues are treated as prohibited performance agents in equine sport, and that the human-outcome evidence for all of them sits elsewhere and remains thin.

Plain-language abstract

This study created a cheaper, simpler laboratory method to detect several performance-related peptides in horse blood as part of anti-doping efforts. Usually these tests rely on costly antibodies to isolate peptides; instead the researchers used a low-cost extraction cartridge followed by high-resolution mass spectrometry to pull out and measure seven peptides at once — including ipamorelin, hexarelin, GHRP-6, CJC-1295, and the active ingredient of TB-500. The method could detect all of them at very low concentrations. To show it worked in practice, the team gave two thoroughbred horses an injection of TB-500 (10 mg) under the skin and successfully detected the compound and one of its breakdown products in their blood. A useful feature is that the stored data can be re-analysed later to search for other peptides not originally targeted. This is a detection-method study only: aside from confirming the drug could be measured after dosing, it does not investigate any health effect, benefit, or side effect of these peptides.